We are live on ! Find out more
DAWN

Day One Biopharmaceuticals
DAWN

Delisted

DAWN was delisted on the 22nd of April, 2026.

Back to rankings

33 hedge funds and large institutions have $401M invested in Day One Biopharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 33 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

29.33% more ownership

Funds ownership: 0% → 29.33% (+29%)

Holders
33
Holders Change
+33
Holders Change %
–
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
33
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$104M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$48.2M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$31.4M
4
Viking Global Investors
Viking Global Investors
Connecticut
+$28M
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$27.1M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$113M +$104M +4,965,588 New
Fidelity Investments
2
Fidelity Investments
Massachusetts
$52.7M +$48.2M +2,312,450 New
T. Rowe Price Associates
3
T. Rowe Price Associates
Maryland
$33.4M +$31.4M +1,505,396 New
Viking Global Investors
4
Viking Global Investors
Connecticut
$30.5M +$28M +1,341,396 New
Janus Henderson Group
5
Janus Henderson Group
United Kingdom
$27.9M +$27.1M +1,297,770 New
BC
6
Boxer Capital
California
$27.1M +$24.8M +1,189,943 New
BI
7
BVF Inc
California
$20.9M +$19.2M +918,975 New
DM
8
Deerfield Management
New York
$18.6M +$17.1M +818,980 New
PA
9
Perceptive Advisors
New York
$17.2M +$15.8M +756,047 New
Vanguard Group
10
Vanguard Group
Pennsylvania
$14.1M +$12.9M +619,384 New
Franklin Resources
11
Franklin Resources
California
$11.8M +$10.8M +518,966 New
DCM
12
Driehaus Capital Management
Illinois
$9.89M +$9.06M +434,423 New
RSCM
13
Rock Springs Capital Management
Maryland
$8.51M +$7.8M +373,739 New
SB
14
Samsara BioCapital
California
$4.61M +$4.22M +202,500 New
HM
15
HealthCor Management
New York
$2.36M +$2.16M +103,717 New
Alyeska Investment Group
16
Alyeska Investment Group
Illinois
$2.35M +$2.15M +103,200 New
LP
17
LMR Partners
United Kingdom
$1.14M +$1.04M +50,000 New
MWNA
18
Marshall Wace North America
New York
$937K +$858K +41,147 New
LGM
19
Logos Global Management
California
$844K +$773K +37,069 New
Geode Capital Management
20
Geode Capital Management
Massachusetts
$795K +$729K +34,935 New
Squarepoint
21
Squarepoint
New York
$431K +$395K +18,927 New
TD Asset Management
22
TD Asset Management
Ontario, Canada
$400K +$352K +16,856 New
Northern Trust
23
Northern Trust
Illinois
$290K +$265K +12,718 New
VF
24
Virtu Financial
New York
$285K +$261K +12,497 New
Goldman Sachs
25
Goldman Sachs
New York
$264K +$242K +11,594 New
1
2

DAWN Hedge Fund Activity: Q2 2021 in Review

33 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q2 2021, worth a combined $401M.

Buyers outnumbered sellers: 33 funds opened new DAWN positions and 0 closed out — a net gain of 33 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $104M.

  • 33 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q2 2021, up from 0 in Q1 2021.
  • Funds reported $401M of Day One Biopharmaceuticals stock for Q2 2021.
  • 33 funds opened new Day One Biopharmaceuticals positions in Q2 2021 and 0 closed out, a net change of +33 holders.
  • The largest Day One Biopharmaceuticals buyer in Q2 2021 was RA Capital Management, an estimated $104M added.

Based on aggregated 13F filings for Q2 2021.